DALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral and laser-delivered Multi-Characteristic Opsin (MCO) gene therapy platforms will be featured in multiple presentations at the 2024 ASGCT Annual Meeting and the Retina World Congress, being held in Baltimore, Maryland and Fort Lauderdale, Florida, respectively, in May.

2024年5月7日，达拉斯/PRNewswire/--Nanoscope Therapeutics Inc.是一家开发视网膜退行性疾病基因治疗的晚期临床生物技术公司，今天宣布其病毒和激光传递的多特征视蛋白（MCO）基因治疗平台将在2024年ASGCT年会和视网膜世界大会上进行多次演讲，这两次会议分别于5月在马里兰州巴尔的摩和佛罗里达州劳德代尔堡举行。

Details are as follows:.

详情如下：。

2024 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

2024年美国基因+细胞治疗学会（ASGCT）年会

Abstract Title: Longitudinal Analysis of BCVA and Near-Field Object Recognition in Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b/3 Randomized, Sham-Controlled, Patient- and Assessor-Masked Clinical Trial (RESTORE)

摘要标题：低剂量或高剂量MCO-010突变不可知的视网膜色素变性光遗传学治疗中BCVA和近场物体识别的纵向分析：2b/3期随机，假对照，患者和评估者掩盖的临床试验（RESTORE）的12个月结果

Abstract/Poster Number: 917

摘要/海报编号：917

Session Type: Poster Session

会议类型：海报会议

Session Title: Wednesday Posters: Gene Therapy Trials - In Vivo Modification

会议标题：周三海报：基因治疗试验-体内修饰

Session Date: May 8, 2024

会议日期：2024年5月8日

Session Time: 12:00 – 7:00 p.m. ET

会议时间：美国东部时间下午12:00–7:00

Presenter: Samuel Barone, MD, Chief Medical Officer

主持人：医学博士Samuel Barone，首席医疗官

Presentation Title: Non-Viral Targeted Laser Delivery of Multi-Characteristic Opsin Genes for Treatment of Geographic Atrophy

演讲标题：非病毒靶向激光递送多特征视蛋白基因治疗地理萎缩

Presentation Number: 426

演示编号：426

Session Type: Oral Abstract Session

会话类型：口头摘要会话

Session Title: Nonviral Approaches for Therapeutic Applications

会议标题：治疗应用的非病毒方法

Session Date: May 11, 2024

会议日期：2024年5月11日

Session Time: 11:15 – 11:30 a.m. ET

会议时间：美国东部时间上午11:15–11:30

Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer

主持人：Samarendra Mohanty博士，总裁兼首席科学官

In this talk, Dr. Mohanty will highlight the advancement of near-infrared laser-delivered MCO-020 platform for the treatment of geographic atrophies (GA) secondary to age-related macular degeneration (AMD).

在这次演讲中，莫汉蒂博士将重点介绍近红外激光传递的MCO-020平台的进展，该平台用于治疗继发于年龄相关性黄斑变性（AMD）的地理性萎缩（GA）。

Retina World Congress 2024

2024年视网膜世界大会

Session Title: Gene Therapy, Pharmacotherapy and Optogenetics for IRD

课程名称：IRD的基因治疗，药物治疗和光遗传学

Session Date: May 9, 2024

会议日期：2024年5月9日

Session Time: 9:05 – 9:35 a.m. ET

会议时间：美国东部时间上午9:05–9:35

Location: Fort Lauderdale Marriott Harbor Beach Hotel

地点：劳德代尔堡海港海滩万豪酒店

Presenter: Samarendra Mohanty, PhD, Chief Scientific Officer

主持人：Samarendra Mohanty博士，首席科学官

Dr. Mohanty will provide a corporate update on Nanoscope's mutation-agnostic MCO-010 gene therapy for vision restoration in patients with inherited retinal degenerations (IRDs). This will be followed by a panel discussion moderated by Peter Kaiser, MD, Professor of Ophthalmology at Cole Eye Institute in Cleveland Clinic Lerner College of Medicine..

莫汉蒂博士将为遗传性视网膜变性（IRD）患者的视力恢复提供Nanoscope突变不可知MCO-010基因治疗的公司最新信息。随后将举行由克利夫兰诊所勒纳医学院科尔眼科研究所眼科教授彼得·凯泽医学博士主持的小组讨论。。

Presentation Title: Longitudinal BCVA and Safety Analysis of Mutation-Agnostic MCO-010 Optogenetic Therapy For Retinitis Pigmentosa: Patient Case From A Phase 2b Randomized, Sham-Controlled, Patient- And Assessor-Masked Clinical Trial (RESTORE)

报告标题：不可知突变的MCO-010光遗传学治疗视网膜色素变性的纵向BCVA和安全性分析：来自2b期随机，假对照，患者和评估者掩盖的临床试验（RESTORE）的患者病例

Session Title: Gene and Cell Therapy

课程名称：基因与细胞疗法

Session Date: May 10, 2024

会议日期：2024年5月10日

Session Time: 2:21 – 2:26 p.m. ET

会议时间：美国东部时间下午2:21–2:26

Location: Fort Lauderdale Marriott Harbor Beach Hotel

地点：劳德代尔堡海港海滩万豪酒店

Presenter: Christine Kay, MD, Director of Electrophysiology, Retinal Genetics, and Clinical Trials at Vitreoretinal Associates in Gainesville, Florida, and Affiliate Assistant Professor at the University of South Florida.

主持人：医学博士克里斯蒂娜·凯（ChristineKay），佛罗里达州盖恩斯维尔玻璃体视网膜协会（Vitreoretinal Associates）电生理学、视网膜遗传学和临床试验主任，南佛罗里达大学附属助理教授。

Dr. Kay will detail the statistically significant and clinically meaningful improvements in visual acuity observed longitudinally for an individual with advanced retinitis pigmentosa (RP) treated with MCO-010 in the RESTORE trial.

凯博士将详细介绍在RESTORE试验中用MCO-010治疗的晚期视网膜色素变性（RP）患者纵向观察到的具有统计学意义和临床意义的视力改善。

About Nanoscope Therapeutics Inc.

关于Nanoscope Therapeutics Inc。

Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S.

Nanoscope Therapeutics正在为数百万遗传性视网膜疾病致盲的患者开发基因不可知的视力恢复光遗传学疗法，目前尚无治愈方法。该公司的主要资产MCO-010最近公布了美国RESTORE 2b期多中心、随机、双盲、假对照临床试验的100周数据。

for RP (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both RP and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for GA due to AMD..

对于RP（NCT04945772）。该公司最近还完成了Stargardt病患者MCO-010治疗的2期STARLIGHT试验（NCT05417126）。MCO-010已获得FDA针对RP和Stargardt病的快速通道指定和FDA孤儿药指定。临床前资产包括非病毒性激光递送的MCO-020基因治疗AMD引起的GA。。

Investor Contact:

投资者联系人：

Argot Partners

Argot合作伙伴

212-600-1902

212-600-1902

PR@nanostherapeutics.com

PR@nanostherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-302137130.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-302137130.html

SOURCE Nanoscope Therapeutics

源Nanoscope Therapeutics